New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:00 EDTSCMP, RNA, PTCT, CBAY, SRPT, BIN, FLML, CWST, SGMO, PZG, FINL, ANETOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
News For ANET;CWST;CBAY;FINL;FLML;PTCT;PZG;BIN;RNA;SGMO;SRPT;SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 30, 2015
11:51 EDTANETArista Networks mentioned cautiously by Markman Advisors
Subscribe for More Information
09:35 EDTFINLFinish Line seen as an attractive target for private equity, says dealReporter
Subscribe for More Information
06:45 EDTBINProgressive Waste reports Q1 adjusted EPS 25c, consensus 24c
Reports Q1 revenue $460.2M, consensus $456.28M.
April 29, 2015
09:39 EDTPTCTHouse Financial Services Committee to hold a hearing
Subscribe for More Information
07:17 EDTSGMOSangamo to present on ZFP therapeutic applications
Subscribe for More Information
April 28, 2015
14:14 EDTCWSTCasella Waste confirms receipt of JCP Investment director nominations
Subscribe for More Information
10:11 EDTSGMOPiper Jaffray biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTCWSTJCP Investment intends to seek election of three director candidates for Casella
Subscribe for More Information
08:03 EDTPTCTPTC Therapeutics announces program targeting BMI1 enters Phase 1 study
Subscribe for More Information
April 27, 2015
10:00 EDTPZGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:21 EDTFINLBofA/Merrill retail/consumer analysts hold analyst/industry conference call
Subscribe for More Information
07:09 EDTPZGParamount Gold and Silver initiated with a Buy at H.C. Wainwright
Target $3.70.
April 23, 2015
10:00 EDTSGMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:18 EDTPTCTOn The Fly: Pre-market Movers
Subscribe for More Information
08:20 EDTCBAYCymaBay initiates Phase 2 study of MBX-8025
CymaBay Therapeutics announced the initiation of a Phase 2 study of MBX-8025 in patients with homozygous familial hypercholesterolemia. MBX-8025 is an orally administered potent and selective peroxisome proliferator-activated receptor delta agonist.
07:51 EDTPTCTPTC Therapeutics price target raised to $155 from $135 at Oppenheimer
Oppenheimer increased its price target on PTC after the company, along with Roche (RHHBY), presented data on its RG7800 drug that the firm believes showed proof-of-mechanism in health subjects. The firm recommends owning PTC ahead of two events: the scheduled October 2015 P3 read-out of Translarna in DMD, and an update on the MOONFISH trial of RG7800 slated to occur in early 2016. The firm keeps an Outperform rating on the shares.
06:18 EDTSGMOSangamo initiated with an Outperform at BMO Capital
Subscribe for More Information
April 22, 2015
16:10 EDTSGMOSangamo sees FY15 revenue $60M-$70M, consensus $67.71M
16:09 EDTSGMOSangamo reports Q1 EPS (8c), consensus (14c)
Reports Q1 revenue $13.5M, consensus $12.5M.
08:14 EDTCBAYCymaBay announces U.S. orphan drug designation for MBX-8025
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use